Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

Open access
Vega, D.M., Yee, L.M., McShane, L.M., Williams, P.M., Chen, L., Vilimas, T., Fabrizio, D., Funari, V., Newberg, J., Bruce, L.K., Chen, S.-J., Baden, J., Carl Barrett, J., Beer, P., Butler, M., Cheng, J.-H., Conroy, J., Cyanam, D., Eyring, K., Garcia, E., Green, G., Gregersen, V.R., Hellmann, M.D., Keefer, L.A., Lasiter, L., Lazar, A.J., Li, M.-C., MacConaill, L.E., Meier, K., Mellert, H., Pabla, S., Pallavajjalla, A., Pestano, G., Salgado, R., Samara, R., Sokol, E.S., Stafford, P., Budczies, J., Stenzinger, A., Tom, W., Valkenburg, K.C., Wang, X.Z., Weigman, V., Xie, M., Xie, Q., Zehir, A., Zhao, C., Zhao, Y., Stewart, M.D., Allen, J.·2021·Annals of Oncology

Abstract

BACKGROUND: Tumor mutational burden (TMB) measurements aid in identifying patients who are likely to benefit from immunotherapy; however, there is empirical variability across panel assays and factors contributing to this variability have not been comprehensively investigated. Identifying sources of variability can help facilitate comparability across different panel assays, which may aid in broader adoption of panel assays and development of clinical applications. MATERIALS AND METHODS: Twenty-nine tumor samples and 10 human-derived cell lines were processed and distributed to 16 laboratories; each used their own bioinformatics pipelines to calculate TMB and compare to whole exome results. Additionally, theoretical positive percent agreement (PPA) and negative percent agreement (NPA) of TMB were estimated. The impact of filtering pathogenic and germline variants on TMB estimates was assessed. Calibration curves specific to each panel assay were developed to facilitate translation of panel TMB values to whole exome sequencing (WES) TMB values. RESULTS: Panel sizes >667 Kb are necessary to maintain adequate PPA and NPA for calling TMB high versus TMB low across the range of cut-offs used in practice. Failure to filter out pathogenic variants when estimating panel TMB resulted in overestimating TMB relative to WES for all assays. Filtering out potential germline variants at >0% population minor allele frequency resulted in the strongest correlation to WES TMB. Application of a calibration approach derived from The Cancer Genome Atlas data, tailored to each panel assay, reduced the spread of panel TMB values around the WES TMB as reflected in lower root mean squared error (RMSE) for 26/29 (90%) of the clinical samples. CONCLUSIONS: Estimation of TMB varies across different panels, with panel size, gene content, and bioinformatics pipelines contributing to empirical variability. Statistical calibration can achieve more consistent results across panels and allows for comparison of TMB values across various panel assays. To promote reproducibility and comparability across assays, a software tool was developed and made publicly available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2021.09.016

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 179

Metadata

Authors
Vega, D. M., Yee, L. M., McShane, L. M., Williams, P. M., Chen, L., Vilimas, T., Fabrizio, D., Funari, V., Newberg, J., Bruce, L. K., Chen, S.-J., Baden, J., Carl Barrett, J., Beer, P., Butler, M., Cheng, J.-H., Conroy, J., Cyanam, D., Eyring, K., Garcia, E., Green, G., Gregersen, V. R., Hellmann, M. D., Keefer, L. A., Lasiter, L., Lazar, A. J., Li, M.-C., MacConaill, L. E., Meier, K., Mellert, H., Pabla, S., Pallavajjalla, A., Pestano, G., Salgado, R., Samara, R., Sokol, E. S., Stafford, P., Budczies, J., Stenzinger, A., Tom, W., Valkenburg, K. C., Wang, X. Z., Weigman, V., Xie, M., Xie, Q., Zehir, A., Zhao, C., Zhao, Y., Stewart, M. D., & Allen, J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-12
Volume
32
Issue
12
Pages
1626-1636
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3203258105
Cited by
179
References
7
FWCI
10.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. https://app.cochat.ai/papers/10.1016/j.annonc.2021.09.016
The paper
Vega, D. M., Yee, L. M., McShane, L. M., Williams, P. M., Chen, L., Vilimas, T., Fabrizio, D., Funari, V., Newberg, J., Bruce, L. K., Chen, S.-J., Baden, J., Carl Barrett, J., Beer, P., Butler, M., Cheng, J.-H., Conroy, J., Cyanam, D., Eyring, K., . . . Allen, J. (2021). Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.09.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.